Previous 10 | Next 10 |
Presented positive topline data from the pivotal Phase 3 REST-ON study Announced today that results of the data analyses for the secondary endpoints of the REST-ON study were consistent with the primary analyses and further demonstrated the overall statistical significance of FT218 co...
Quick Take Harmony Biosciences Holdings ( HRMY ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The firm is a biopharma commercializing its WAKIX molecule for the treatment of excessive sleepiness in adult narcolepsy. HRMY has...
DUBLIN, Ireland, July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 10, 2020, to provide a corporate update and discuss the Company's financial results for the sec...
Last week, we provided a ' deep dive ' on Jazz Pharmaceuticals ( JAZZ ). After the research, we passed on making any investment recommendation on the mid-cap biopharma. In part, this was because there was a potentially better candidate in the pipeline of a much smaller biopharma that could b...
Equillium Reports Positive Data for COVID-19 Drug Trial Equillium Inc. (EQ) reported positive data for its COVID-19 drug itolizumab. The data showed that the drug candidate was useful in lowering the risk of mortality in patients suffering from coronavirus. The results were declared by i...
Avadel Pharmaceuticals ( AVDL +0.9% ) has dosed first patient in an open-label extension/switch study of FT218, a once-nightly formulation of sodium oxybate, for excessive daytime sleepiness and cataplexy in patients with narcolepsy. More news on: Avadel Pharmaceuticals plc...
Clinical study to enroll 250 patients from sites that participated in the REST-ON study Study to examine the long-term safety and maintenance of efficacy in patients, and evaluate dosing and preference for patients switching from twice-nightly sodium oxybate to once-nightly FT218 ...
Fate is just another word for people's choices coming to a head. Destiny, coincidence, whatever you name it. It inevitably lies in our hands ." - Tiffanie DeBartolo It has been quite a while since we looked at this mid-cap biopharma below. The shares have seen better days, but there are s...
Avadel Pharmaceuticals ( AVDL -1.4% ) sold its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz, Vazculep, and Akovaz, as well as Nouress to Exela Sterile Medicines LLC for a total of $42M. More news on: Avadel Pharmaceu...
DUBLIN, Ireland, July 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today...
News, Short Squeeze, Breakout and More Instantly...
Avadel Pharmaceuticals plc Company Name:
AVDL Stock Symbol:
NASDAQ Market:
Avadel Pharmaceuticals plc Website:
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Ind...
2024-05-29 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -...